Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?

J Clin Oncol. 2021 Nov 1;39(31):3423-3426. doi: 10.1200/JCO.21.01371. Epub 2021 Sep 20.

Authors

Mark J Ratain^{1

2}, Ian F Tannock^{2

3}, Allen S Lichter²

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
² Optimal Cancer Care Alliance, Ann Arbor, MI.
³ Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada.

PMID: 34543056
DOI: 10.1200/JCO.21.01371

No abstract available

MeSH terms

Drug-Related Side Effects and Adverse Reactions / prevention & control*
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Maximum Tolerated Dose*
Neoplasms / drug therapy*
Piperazines / therapeutic use*
Pyridines / therapeutic use*
Pyrimidines / therapeutic use*
United States
United States Food and Drug Administration

Substances

Immune Checkpoint Inhibitors
Piperazines
Pyridines
Pyrimidines
sotorasib